Cellenkos, Inc., established in 2016, is a clinical stage biotechnology company with a focus on developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Pioneered from a proprietary platform licensed from MD Anderson Cancer Center, Cellenkos leverages its CRANE® Platform for the selection and enrichment of umbilical cord blood-derived Tregs, offering specialized solutions across areas such as oncology and neurology.
Distinguished by the capability of manufacturing therapies that do not require HLA matching, these treatments can be rapidly produced and administered on an outpatient basis. The company operates within the Biotechnology industry, yet its geographical base remains unspecified.
On 04 November 2021, Cellenkos secured a $15.00M Series A investment, backed notably by BVCF. As Cellenkos progresses through its clinical stages, it presents a compelling proposition for investors seeking to capitalize on the burgeoning market of innovative immune-modulatory therapies.
